Rutgers Shield Logo

Rutgers University signs two agreements with Santhera Pharmaceuticals to advance pioneering research for the treatment of congenital muscular dystrophy. The agreements complement ongoing research of Peter Yurchenco, professor at Rutgers Robert Wood Johnson Medical School and a pioneer in a novel gene therapy approach for the treatment of LAMA2-deficient congenital muscular dystrophy.